4basebio UK Societas Admission to Trading on AIM and First Day of Dealings
4basebio UK Societas
("4basebio", the "Company" or the "Group")
Admission to Trading on AIM and First Day of Dealings
4basebio UK Societas (AIM: 4BB), the specialist life sciences group focused on
exploiting its intellectual property in the field of gene therapies and DNA
vaccines, is pleased to announce the admission of its ordinary shares to
trading on the AIM market of the London Stock Exchange. Dealings will commence
at 8.00 a.m. today, Wednesday 17 February 2021, under the ticker 4BB
Upon Admission, the Company will have 12,317,473 ordinary shares in issue and a
market capitalisation of approximately £14.5 million.
Heikki Lanckriet, Chief Executive Officer of 4basebio, commented:
"We are delighted to be admitted to AIM today. As a Cambridge based company
with significant ambitions, we believe AIM is the ideal market to support our
further development. We would also like to extend our thanks to our staff,
advisors and shareholders who continue to support our ongoing growth strategy."
Cairn Financial Advisers LLP is acting as Nominated Adviser to the Company and
finnCap is acting as Broker.
4basebio is a specialist life sciences group focused on therapeutic DNA for
gene therapies and DNA vaccines and providing solutions for effective and safe
delivery of these DNA based products to patients. It is the intention of the
Company to become a market leader in the manufacture and supply of high purity,
synthetic DNA for research, therapeutic and pharmacological use. The immediate
objectives of 4bb are to validate and scale its DNA synthesis and advance its
collaborations to facilitate the functional validation of its DNA based
products and gene delivery solutions.
The Company divested from 4basebio AG ("4bb AG"), a German company listed on
the Prime Standard segment of the Frankfurt Stock Exchange, following the
disposal by 4bb AG (then named Expedeon AG) of its proteomics and immunology
business to AIM-quoted Abcam plc in January 2020 for ?120million. Following the
disposal, 4bb AG retained its genomics business which owned and licensed
certain intellectual property including its proprietary, patent-protected
technology, TruePrimeT. This is the foundation for building the Company's
synthetic DNA manufacturing business which 4bb AG transferred to the Company
along with funding to continue the Company's development and investment.
On Admission, the Company will have cash reserves of approximately £14.4million
which the Directors consider will provide sufficient working capital for the
development and scale-up of the business to commercialisation.
The Company has a wholly-owned Spanish subsidiary, 4basebio S.L.U. ("4bb
Spain") and a wholly-owned UK subsidiary, 4basebio UK Limited ("4bb UK") which
in turn wholly-owns 4basebio Discovery Limited ("4bb Discovery").
4bb UK focuses on the DNA validation and scaling work required as a
prerequisite to developing Good Manufacturing Practice ("GMP") grade DNA,
suitable for use in gene therapies and DNA vaccines. It is expected that 4bb
UK's operations will continue to expand as it becomes the Group's centre of
4bb Discovery was created as a particle and indication research and development
arm of the Group with the intention of developing intellectual property around
non-viral delivery platforms.
4bb Spain undertakes primary DNA synthesis research and is involved in the
manufacture of enzymes used in the DNA manufacturing process as well as in
other diagnostic and research applications.
The Admission Document can be found on 4basebio's website: www.4basebio.com
For further enquiries, please contact:
4basebio UK Societas +44 (0)12 2396 7943
Nominated Adviser +44 (0)20 7213 0880
Cairn Financial Advisers LLP
Jo Tuner / Sandy Jamieson
Broker +44 (0)20 7220 0500
Richard Chambers/Charlotte Sutcliffe
Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed to be, forward
looking statements. Forward looking statements are identi?ed by their use of
terms and phrases such as "believe", "could", "should" "envisage",
"estimate", "intend", "may", "plan", "potentially", "expect",
"will" or the negative of those, variations or comparable expressions,
including references to assumptions. These forward-looking statements are not
based on historical facts but rather on the Directors' current expectations and
assumptions regarding the Company's future growth, results of operations,
performance, future capital and other expenditures (including the amount,
nature and sources of funding thereof), competitive advantages, business
prospects and opportunities. Such forward looking statements re?ect the
Directors' current beliefs and assumptions and are based on information
currently available to the Directors.
(END) Dow Jones Newswires
February 17, 2021 02:00 ET (07:00 GMT)